VanEck Associates’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-25,977
| Closed | -$4.51M | – | 1424 |
|
|
2025
Q4 | $4.51M | Buy |
25,977
+174
| +0.7% | +$31.7K | ﹤0.01% | 819 |
|
|
2025
Q3 | $4.92M | Sell |
25,803
-208
| -0.8% | -$36.9K | ﹤0.01% | 774 |
|
|
2025
Q2 | $4.67M | Sell |
26,011
-1,373
| -5% | -$238K | 0.01% | 755 |
|
|
2025
Q1 | $4.63M | Buy |
27,384
+3,186
| +13% | +$523K | 0.01% | 736 |
|
|
2024
Q4 | $3.65M | Buy |
24,198
+21,958
| +980% | +$3.42M | ﹤0.01% | 804 |
|
|
2024
Q3 | $352K | Sell |
2,240
-18,879
| -89% | -$2.82M | ﹤0.01% | 1125 |
|
|
2024
Q2 | $2.89M | Buy |
21,119
+1,563
| +8% | +$214K | ﹤0.01% | 772 |
|
|
2024
Q1 | $2.6M | Buy |
19,556
+17,284
| +761% | +$2.24M | ﹤0.01% | 783 |
|
|
2023
Q4 | $313K | Sell |
2,272
-275
| -11% | -$36.2K | ﹤0.01% | 1109 |
|
|
2023
Q3 | $311K | Buy |
2,547
+25
| +1% | +$3.33K | ﹤0.01% | 1102 |
|
|
2023
Q2 | $355K | Sell |
2,522
-12,269
| -83% | -$1.69M | ﹤0.01% | 1095 |
|
|
2023
Q1 | $2.09M | Buy |
14,791
+21
| +0.1% | +$3K | ﹤0.01% | 700 |
|
|
2022
Q4 | $2.31M | Sell |
14,770
-5,241
| -26% | -$753K | 0.01% | 649 |
|
|
2022
Q3 | $2.46M | Sell |
20,011
-6,695
| -25% | -$882K | 0.01% | 600 |
|
|
2022
Q2 | $3.55M | Sell |
26,706
-2,884
| -10% | -$393K | 0.01% | 539 |
|
|
2022
Q1 | $4.05M | Buy |
29,590
+4,185
| +16% | +$583K | 0.01% | 551 |
|
|
2021
Q4 | $4.39M | Buy |
25,405
+3,725
| +17% | +$567K | 0.01% | 533 |
|
|
2021
Q3 | $3.15M | Buy |
21,680
+2,077
| +11% | +$304K | 0.01% | 562 |
|
|
2021
Q2 | $2.59M | Buy |
19,603
+11,878
| +154% | +$1.56M | 0.01% | 602 |
|
|
2021
Q1 | $991K | Buy |
7,725
+6,440
| +501% | +$794K | ﹤0.01% | 743 |
|
|
2020
Q4 | $153K | Buy |
1,285
+243
| +23% | +$29.6K | ﹤0.01% | 871 |
|
|
2020
Q3 | $119K | Buy |
1,042
+182
| +21% | +$21.5K | ﹤0.01% | 865 |
|
|
2020
Q2 | $98K | Buy |
860
+175
| +26% | +$18.6K | ﹤0.01% | 857 |
|
|
2020
Q1 | $55K | Sell |
685
-358
| -34% | -$37.1K | ﹤0.01% | 864 |
|
|
2019
Q4 | $111K | Sell |
1,043
-26
| -2% | -$2.71K | ﹤0.01% | 840 |
|
|
2019
Q3 | $114K | Buy |
1,069
+264
| +33% | +$27.1K | ﹤0.01% | 746 |
|
|
2019
Q2 | $82K | Buy |
805
+558
| +226% | +$53.6K | ﹤0.01% | 753 |
|
|
2019
Q1 | $22K | Buy |
247
+207
| +518% | +$17.9K | ﹤0.01% | 816 |
|
|
2018
Q4 | $3K | Buy |
+40
| New | +$3.75K | ﹤0.01% | 819 |
|
|
2018
Q2 | – | Sell |
-94
| Closed | -$9K | – | 854 |
|
|
2018
Q1 | $9K | Buy |
+94
| New | +$9.63K | ﹤0.01% | 733 |
|
Other funds holding DGX
EIG
VanEck Associates's DGX Position: Q1 2026 in Review
VanEck Associates sold out of Quest Diagnostics (DGX) in Q1 2026, closing a stake of 25,977 shares — an estimated $4.51M sold.
VanEck Associates first reported a position in DGX in Q1 2018 and held it in 30 quarters. The position peaked at $4.92M in Q3 2025. 1,067 funds tracked by Wall St. Rank hold DGX as of Q1 2026.
- VanEck Associates reported no remaining Quest Diagnostics position as of Q1 2026 after selling out during the quarter.
- VanEck Associates sold 25,977 Quest Diagnostics shares in Q1 2026, an estimated $4.51M.
- VanEck Associates first reported a position in Quest Diagnostics in Q1 2018 and held it in 30 quarters.
- VanEck Associates's Quest Diagnostics position peaked at $4.92M in Q3 2025.
- 1,067 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.
Based on VanEck Associates's 13F filing for Q1 2026, filed 15 May 2026.